Chronic viral hepatitis, the treatment with spiruline for one month has no effect on the aminotransferases

Rom J Intern Med. 2002;40(1-4):89-94.


Context: Spirulina platensis is extracted from an alga and theoretically has many good effects on the majority of the organs. There is not any published clinical trial on humans.

Objective: The evaluation of the efficacy of spiruline in chronic viral liver disease.

Design: Double blind, randomised clinical trial.

Setting: Secondary care university hospital.

Patients: 24 patients with chronic viral liver disease, treated with spiruline or placebo for one month.

Outcome measurement: Aminotransferases diminution and the modification of a general state score self-evaluated by the patient on an analogic visual scale.

Results: A modification of the aminotransferases level in the detriment of the spiruline treated group has been found (p = 0.036 for ALAT, p = 0.017 for ASAT), and not at the level of the general state score (p = 0.30).

Conclusion: Despite the little number of patients, significant results not favouring spiruline have been found.

Publication types

  • Clinical Trial
  • Randomized Controlled Trial
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Antiviral Agents / therapeutic use*
  • Bacterial Proteins / therapeutic use*
  • Cyanobacteria
  • Double-Blind Method
  • Hepatitis B, Chronic / blood
  • Hepatitis B, Chronic / drug therapy*
  • Hepatitis C, Chronic / blood
  • Hepatitis C, Chronic / drug therapy*
  • Humans
  • Middle Aged
  • Spirulina
  • Transaminases / blood*
  • Treatment Outcome


  • Antiviral Agents
  • Bacterial Proteins
  • Transaminases